摘要
目的:分析慢性心力衰竭患者应用沙库巴曲缬沙坦联合螺内酯治疗的临床疗效。方法:此次研究时间为2020年1月—2022年5月,研究对象为80例,均来自本院收治的慢性心力衰竭患者,所有患者按照随机表法分成2组,即实验组(n=40)与对照组(n=40),对照组患者予以缬沙坦联合螺内酯治疗,实验组患者予以沙库巴曲缬沙坦联合螺内酯治疗,对比两种不同治疗方案带给患者的变化。结果:实验组患者的治疗总有效率为95.00%,显著高于对照组的77.50%(P<0.05)。治疗前,实验组与对照组患者的LVEDD、LVESD、LVEF、6min步行距离、NT-proBNP、CRP对比,无显著差异(P>0.05)。治疗后,实验组患者的LVEDD、LVESD比对照组小,LVEF高于对照组,CRP、NT-proBNP低于对照组,6min步行距离比对照组远(P<0.05)。结论:慢性心力衰竭患者应用沙库巴曲缬沙坦联合螺内酯治疗可改善心功能、提升运动耐量,抑制炎性反应,进而提高治疗效果。
Objective:To analyze the clinical effect of Shakubartrivalsartan combined with spironolactone in patients with chronic heart failure.Method:This study lasted from January 2020 to May 2022,and 80 cases were studied,all of which were patients with chronic heart failure admitted to our hospital.All patients were divided into two groups according to the randomized table method,namely the experimental group(n=40)and the control group(n=40),and the control group was treated with valsartan combined with spironolide.The experimental group was treated with shakubactrivalsartan combined with spironolactone,and the changes brought by two different treatment schemes were compared.Results:The total effective rate of treatment in the experimental group was 95.00%,which was significantly higher than 77.50%in the control group(P<0.05).Before treatment,there was no significant difference in LVEDD,LVESD,LVEF,6-min walking distance,NT-proBNP,and CRP between the experimental group and the control group(P>0.05).After treatment,LVEDD and LVESD in the experimental group were smaller than those in the control group,LVEF was higher than that in the control group,CRP and NT-proBNP were lower than those in the control group,and the 6-min walking distance was longer than that in the control group(P<0.05).Conclusion:The treatment of patients with chronic heart failure with Shakubactrivalsartan combined with spironolactone can improve cardiac function,enhance exercise tolerance,inhibit inflammatory response,and thus improve the therapeutic effect.
作者
尹辉
王卓
肖红刚
马国超
Yin Hui(Dongguan Renkang Hospital,Dongguan Guangdong 523000)
出处
《黑龙江医药》
CAS
2023年第3期501-504,共4页
Heilongjiang Medicine journal
基金
东莞市社会发展科技项目(项目编号:20231800903172)。
关键词
沙库巴曲缬沙坦
螺内酯
慢性心力衰竭
心功能
Shakubartrivalsartan
Spironolactone
Chronic Heart Failure
Cardiac Function